Cargando…

Complete response in patient with liver metastasis of HER2-positive breast cancer following therapy with margetuximab: a case report

Metastatic human epidermal growth factor receptor 2 (HER2) positive breast cancer has a poor prognosis and few effective targeted therapies. However, several anti-HER2 agents are emerging in conjunction with chemotherapy, which may lead to increased rates of pathological complete response in patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang, Haiyan, Hu, Ting, Hu, Jie, Ding, Teng, Wang, Qiong, Cheng, Jing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344431/ https://www.ncbi.nlm.nih.gov/pubmed/36730303 http://dx.doi.org/10.1097/CAD.0000000000001466

Ejemplares similares

Profile of Margetuximab: Evidence to Date in the Targeted Treatment of Metastatic HER2-positive Breast Cancer
por: Schlam, Ilana, et al.
Publicado: (2022)

A Review of Margetuximab-Based Therapies in Patients with HER2-Positive Metastatic Breast Cancer
por: Alasmari, Moudi M.
Publicado: (2022)

Margetuximab: An active alternative for later‐line therapy in patients with HER2‐positive advanced breast cancer
por: Zhou, Yunxiang, et al.
Publicado: (2023)

Significant response to margetuximab in Chinese HER2-positive metastatic breast cancer patient who progressed after second-line targeted therapy
por: Li, Jiaping, et al.
Publicado: (2023)

Economic evaluation of margetuximab vs. trastuzumab for pretreated ERBB2-positive advanced breast cancer in the US and China
por: Tang, Zhiyuan, et al.
Publicado: (2022)

Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial
por: Rugo, Hope S., et al.
Publicado: (2023)

Complete pathologic response of HER2-positive breast cancer liver metastasis with dual Anti-HER2 antagonism
por: Schoellhammer, Hans F, et al.
Publicado: (2014)

Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A
por: Catenacci, D.V.T., et al.
Publicado: (2022)

Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial
por: Rugo, Hope S., et al.
Publicado: (2021)

Appendicitis caused by the metastasis of HER2-positive breast cancer
por: Mori, Ryutaro, et al.
Publicado: (2016)

Safety and Efficacy of Human Epidermal Growth Factor Receptor 2-Targeted Therapies in Advanced Breast Cancer: A Head-to-Head Comparison of Margetuximab versus Trastuzumab
por: Zhang, Liyi
Publicado: (2021)

Effective Treatment of Solitary Pituitary Metastasis with Panhypopituitarism in HER2-Positive Breast Cancer by Lapatinib
por: Park, Youngmok, et al.
Publicado: (2016)

Using the HER2/CEP17 FISH Ratio to Predict Pathologic Complete Response Following Neoadjuvant Anti-HER2 Doublet Therapy in HER2+ Breast Cancer
por: Lander, Eric M, et al.
Publicado: (2022)

Complete response to pyrotinib combined with letrozole as first-line treatment of HER2-positive/HR-positive breast cancer: a case report
por: Xie, Ning, et al.
Publicado: (2021)

HER2‐positive breast cancer brain metastasis: A new and exciting landscape
por: Zimmer, Alexandra S., et al.
Publicado: (2020)

SDPS-10 DISPARITIES IN THE RISK OF CNS METASTASIS AND CLINICAL OUTCOMES IN PATIENTS WITH HER2- MUTATION POSITIVE (HER2+) NON-BREAST VERSUS HER2+ BREAST CANCERS
por: Elghawy, Omar, et al.
Publicado: (2023)

Pathologic complete response to neoadjuvant anti-HER2 therapy is associated with HER2 immunohistochemistry score in HER2-positive early breast cancer
por: Chen, Hai-long, et al.
Publicado: (2021)

A Case of Pathological Complete Response and Resolution of Dermatomyositis Following Neoadjuvant Chemotherapy in HER2-Positive Early Breast Cancer
por: Piras, Marta, et al.
Publicado: (2021)

Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
por: Ding, Yi, et al.
Publicado: (2018)

WASF3 provides the conduit to facilitate invasion and metastasis in breast cancer cells through HER2/HER3 signaling
por: Teng, Yong, et al.
Publicado: (2016)

MiR-221 promotes trastuzumab-resistance and metastasis in HER2-positive breast cancers by targeting PTEN
por: Ye, Xingming, et al.
Publicado: (2014)

Liquid biopsy for HER2-positive breast cancer brain metastasis: the role of the cerebrospinal fluid
por: De Mattos-Arruda, Leticia
Publicado: (2017)

Follistatin is a metastasis suppressor in a mouse model of HER2-positive breast cancer
por: Seachrist, Darcie D., et al.
Publicado: (2017)

Efficacy of a HER2-Targeted Thorium-227 Conjugate in a HER2-Positive Breast Cancer Bone Metastasis Model
por: Karlsson, Jenny, et al.
Publicado: (2023)

Liver resection for HER2-enriched breast cancer metastasis: case report and review of the literature
por: Temukai, Mai, et al.
Publicado: (2017)

The Synergistic Effects of Pyrotinib Combined With Adriamycin on HER2-Positive Breast Cancer
por: Wang, Chaokun, et al.
Publicado: (2021)

Pyrotinib Treatment in Patients With HER2-positive Metastatic Breast Cancer and Brain Metastasis: Exploratory Final Analysis of Real-World, Multicenter Data
por: Anwar, Munawar, et al.
Publicado: (2021)

The efficacy and safety of pyrotinib in treating HER2‐positive breast cancer patients with brain metastasis: A multicenter study
por: Gao, Min, et al.
Publicado: (2021)

Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer
por: Katayama, Ayaka, et al.
Publicado: (2021)

Immune cell profiles of metastatic HER2-positive breast cancer patients according to the sites of metastasis
por: Honkanen, Tiia J., et al.
Publicado: (2021)

Identification of key genes in HER2-positive breast cancer with brain metastasis via bioinformatics methods
por: Yang, Ziguo, et al.
Publicado: (2023)

Predictive factors of pathologic complete response in HER2-positive and axillary lymph node positive breast cancer after neoadjuvant paclitaxel, carboplatin plus with trastuzumab
por: Ding, Jinhua, et al.
Publicado: (2017)

miR-135b-5p enhances the sensitivity of HER-2 positive breast cancer to trastuzumab via binding to cyclin D2
por: Li, Zhilan, et al.
Publicado: (2020)

Complete pathological response in patients with HER2 positive breast cancer treated with neoadjuvant therapy in Colombia
por: Rodríguez, Mauricio, et al.
Publicado: (2023)

HER2-positive breast cancer patients receiving trastuzumab treatment obtain prognosis comparable with that of HER2-negative breast cancer patients
por: Qin, Tao, et al.
Publicado: (2013)

Predicting acute radiation dermatitis in breast cancer: a prospective cohort study
por: Xie, Yuxiu, et al.
Publicado: (2023)

HER2/positive and HER2/low in inflammatory breast cancer recurrence
por: Movchan, Oleksii Volodimirovich, et al.
Publicado: (2022)

Immunotherapy for HER-2 positive breast cancer
por: Yang, Tingting, et al.
Publicado: (2023)

A Nomogram for Predicting Liver Metastasis of Lymph-Node Positive Luminal B HER2 Negative Subtype Breast Cancer by Analyzing the Clinicopathological Characteristics of Patients with Breast Cancer
por: Yue, Yuhan, et al.
Publicado: (2022)

Prophylactic cranial irradiation reduces the incidence of brain metastasis in a mouse model of metastatic, HER2-positive breast cancer
por: Smith, Daniel L., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gtd917891c41j4i3q54lok9nmi